-
1.发明授权Screening for agents effective in decreasing abnormal macrophages associated with amyotrophic lateral sclerosis 失效筛选有效减少与肌萎缩性侧索硬化有关的异常巨噬细胞的药剂公开(公告)号：US07198946B2
公开(公告)日：2007-04-03
申请号：US10299946
申请日：2002-11-18
CPC分类号： A61K31/00 , A61K31/13 , A61K31/135 , A61K31/198 , G01N33/56972 , G01N33/6893 , G01N2333/70535 , G01N2333/70596 , G01N2500/04 , G01N2500/10 , G01N2800/28
摘要： The invention provides methods of monitoring amyotrophic lateral sclerosis (ALS) disease development or progression and monitoring an ALS therapy by determining the level of HLA-DR expression by CD14+ monocytes and/or the percentage of CD16+ cells in the population of CD14+ cells and/or the number of CD14+/CD16+ cells in peripheral blood of an individual with ALS. The invention is also directed to methods for decreasing the number of circulating CD14+ monocytes and/or the population of CD14+/CD16+ cells and/or the number of CD14+/CD16+ cells in an individual with ALS. The invention is also directed to methods of screening for agents which decrease the population of CD14+ monocytes with elevated HLA-DR expression and/or the population of CD14+/CD16+ cells and/or the number of CD14+/CD16+ cells in an individual with ALS.
摘要翻译： 本发明提供了通过测定CD14 +单核细胞的HLA-DR表达水平和/或CD14 +细胞群体中CD16 +细胞的百分比和/或其它方法来监测肌萎缩性侧索硬化（ALS）疾病发展或进展并监测ALS治疗的方法。 ALS患者外周血CD14 + / CD16 +细胞数。 本发明还涉及用于减少患有ALS的个体中CD14 + / CD16 +细胞循环CD14 +和/或CD14 + / CD16 +细胞数量和/或CD14 + / CD16 +细胞数量的方法。 本发明还涉及筛选在具有ALS的个体中降低HLA-DR表达和/或CD14 + / CD16 +细胞群体和/或CD14 + / CD16 +细胞数目的CD14 +单核细胞群体的试剂的方法。
-
公开(公告)号：US07902185B2
公开(公告)日：2011-03-08
申请号：US10453912
申请日：2003-06-03
申请人： Tennore M. Ramesh , Sean Scott
发明人： Tennore M. Ramesh , Sean Scott
CPC分类号： G01N33/6896 , A61K31/00 , A61K31/427 , A61K31/472 , A61K31/4725 , A61K31/496 , A61K31/513 , A61K31/551 , A61K31/635 , G01N2333/4703
摘要： Methods for modulating proteasome activity in a subject is provided. Proteasome activity is modulated by administering a therapeutically effective amount of proteasome modulating pharmacological agent to a subject. In a preferred embodiment, the proteasome modulating pharmacological agent is a protease inhibitor. In another aspect, a screening assay for detecting and identifying proteasome modulating pharmacological agents to modulate proteasome activity in a subject is also provided.
摘要翻译： 提供了调节受试者中蛋白酶体活性的方法。 通过向受试者施用治疗有效量的调节蛋白酶体的药理学试剂来调节蛋白酶体活性。 在优选的实施方案中，蛋白酶体调节药理学试剂是蛋白酶抑制剂。 另一方面，还提供了用于检测和鉴定蛋白酶体调节药理学试剂以调节受试者中蛋白酶体活性的筛选测定。
-
搜索结果
2 条记录 (耗时 0.02 秒)
